(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2015 (11.06.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/083101 A1

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2014/066558

(22) International Filing Date:
3 December 2014 (03.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13306679.5 6 December 2013 (06.12.2013) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants *(for US only)*: **DI TOMASO, Emmanuelle** [FR/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **GERMA, Marie-Caroline** [FR/FR]; c/o Novartis Pharma S.A.S., Boite Postale 308, F-92506 Rueil-Malmaison Cedex (FR). **MASSACESI, Cristian** [IT/FR]; c/o Novartis Pharma S.A.S., Boite Postale 308, F-92506 Rueil-Malmaison (FR). **FRITSCH, Christine** [FR/CH]; c/o Novartis Pharma AG, NIBR Klybeck Novartis, Institutes for Biomedical Research, Postfach, CH-4002 Basel (CH). **SCHNELL, Christian Rene** [FR/CH]; c/o Novartis Pharma AG, NIBR Klybeck Novartis, Institutes for Biomedical Research, Postfach, CH-4002 Basel (CH). **TAVORATH, Ranjana** [US/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 (US).


(74) Agent: **RUECK, Sandra**; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,

[Continued on next page]

(54) Title: DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR

Fig. 1



(57) Abstract: The present invention relates to an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for use in methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of said compound for at least two five-consecutive day cycles, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles.

WO 2015/083101 A1

SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*